In this brief presentation, Director of the Rena Rowan Breast Center Kevin Fox, MD, explains the function, significance and pathology of the human epidermal growth factor receptor 2 (HER2) gene in heritable breast cancer, as well as current treatments to prevent recurrence in women with HER2+ disease, and the issues presented by recent clinical trials of the HER dimerization inhibitor pertuzumab and the oral kinase inhibitor neratinib.
Related Links:
Enrolling Clinical Trials: Proton Radiotherapy for Accelerated Partial Breast Irradiation in Stage 0, I & II Breast Cancer
Dr Fox's Penn Medicine Profile
Dr Fox's Doximity Profile
Published
February 13, 2018
Created by
BROADCASTMED